CLAIMS

1. A recombinant adeno-associated virus (rAAV) comprising (i) a variant AAV capsid protein comprising a heterologous peptide with a length of 7, 8, 9, 10 or 11 amino acids covalently inserted in the GH-loop of the capsid protein relative to a corresponding parental AAV capsid protein, wherein the peptide insertion comprises the amino acid sequence ISDQTKH (SEQ ID NO:1) and (ii) a heterologous nucleic acid comprising a nucleotide sequence encoding a complement regulator factor H (CFH) protein fragment wherein the CFH protein

   fragment comprises SCR l-4, 6-8, and 17-20, and wherein the CFH protein fragment does not comprise SCR5 and SCR9-16.
2. The rAAV according to claim 1, wherein the insertion peptide is LAISDQTKHA (SEQ ID NO:2).
3. The rAAV according to claim 1, wherein the insertion site is located between amino acids corresponding to amino acids 587 and 588 of VP1 of AAV2 (SEQ ID NO:47) or the corresponding position in the capsid protein of another AAV serotype.
4. The rAAV according to claim 1, wherein the capsid protein comprises a P34A amino acid substitution relative to VP1 of AAV2 and comprises an amino acid sequence at least 95% identical to the entire length of the amino acid sequence set forth as SEQ ID NO:42, preferably wherein the capsid protein consists of the amino acid sequence set forth as SEQ ID NO:42.
5. The rAAV according to claim 1, wherein the variant AAV capsid protein comprises an amino acid sequence with 100% sequence identity to the amino acid sequence set forth in SEQ ID NO:42.
6. The rAAV according to claim 1, wherein the rAAV comprises a heterologous acid comprising from 5' to 3': (a) an inverted terminal repeat (b) a promoter (c) a nucleotide sequence encoding the CFH protein or a fragment thereof (d) a polyadenylation sequence and/or a WPRE sequence and (e) an inverted terminal repeat.
7. The rAAV according to claim 1, wherein the CFH protein fragment comprises at least a linker of 1 to about 18 amino acids located between one or more of the SCRs.

8. The rAAV according to claim 7, wherein the CFH protein fragment comprises SCRl-(Ll)- SCR2-(L2)-SCR3-(L3)-SCR4-(L4)-(SCR6-(L4'))-SCR7-(L5)-(SCR8-(L5'))-(SCR16-(L5''))-(SCR17-(L5'''))-(SCR18-(L5''''))-SCR19-(L6)-SCR20, wherein the () indicate optional component(s), "L" refers to a linker, and each of LI, L2, L3, L4, L4', L5, L5', L5'', L5''', L5'''' and L6 may be absent or independently selected from an amino acid sequence of about 1 to about 12 to about 18 amino acids.

9. The rAAV according to claim 8, wherein the CFH protein fragment comprises an amino acid sequence with at least 95% sequence identity to the amino acid sequence set forth in SEQ ID NO:34.

10. The rAAV according to claim 8, wherein the CFH protein fragment comprises an amino acid sequence that is 100% identical to the amino acid sequence set forth in SEQ ID NO:34.

11. The rAAV according to claim 8, wherein the CFH protein fragment comprises at least one glycosylation site in one or more of the SCRs.

12. The rAAV according to claim 11, wherein the glycosylation site is engineered into one or more of SCR17 and/or SCR18.

13. The rAAV according to claim 11, wherein the CFH protein fragment comprises SCRl-4, 6-8, and 17-20 and wherein the glycosylation site is engineered into SCR 17 and SCR18, and wherein the CFH protein fragment does not comprise SCR5 and SCR9-16.

14. The rAAV according to claim 13, wherein the CFH protein fragment comprises an amino acid sequence with 100% sequence identity to the sequence set forth in SEQ ID NO:34 and wherein the glycosylation site is engineered into SCR17 and SCR18.

15. The rAAV according to claim 6, wherein the promoter is a ubiquitous promoter, optionally a CAG promoter.

16. The rAAV according to claim 15, wherein the rAAV comprises a heterologous nucleic acid comprising a nucleotide sequence with at least 95% sequence identity to the nucleotide sequence set forth in any one of SEQ ID NOs:43-46.

17. The rAAV according to claim 15, wherein the rAAV comprises a heterologous nucleic acid comprising the nucleotide sequence set forth in any one of SEQ ID NOs:43-46.

18. A host cell comprising the rAAV according to claim 17.

19. A pharmaceutical composition comprising the rAAV according to claim 16 and a pharmaceutically acceptable carrier, diluent, excipient or buffer.

20. Use of the pharmaceutical composition according to claim 19 in the manufacture of a medicament for the treatment of dry age-related macular disorder (dry AMD), wherein the pharmaceutical composition is to be administered in a subject in need thereof by intravitreal, suprachoroidal or subretinal administration.

21. Use of the pharmaceutical composition according to claim 19 in the manufacture of a medicament for the treatment of geographic atrophy (GA), wherein a therapeutically effective amount of the pharmaceutical composition is to be administered in a subject in need thereof by periocular, intravitreal, suprachoroidal or subretinal administration.